Furthermore, co-localization of anti-PEG, anti-HER2, and anti-cytokeratin antibodies was observed in multiple tumor biopsies that were collected 72 h after MM-302 treatment, confirming the HER2-targeting property of MM-302. The gene discussed is ERBB2; the disease is neoplasm.